Denver, CONCT06722235Now EnrollingIRB Ready

Immune Thrombocytopenia Clinical Trial in Denver, CO

Access cutting-edge immune thrombocytopenia treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions...

Expert Care in Denver

Access immune thrombocytopenia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related immune thrombocytopenia treatment provided free

Apply for This Denver Location

Check if you qualify for this immune thrombocytopenia clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Immune Thrombocytopenia Study in Denver

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active in

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

The participant has been diagnosed with ITP that has persisted for at least 12 months. 2. The participant's diagnosis of ITP is supported by a prior response to an ITP therapy (not including a thrombopoietin receptor agonist \[TPO-RA\]), defined as having achieved a platelet count ≥50,000/μL. 3. The participant has evidence of insufficient response or intolerance to at least 1 currently available first-line therapy for treatment of ITP (for example, corticosteroids), and at least 1 currently available second-line therapy for treatment of ITP (for example, TPO-RA, rituximab, fostamatinib, mycophenolate). Insufficient response to previous treatment is defined as failure to achieve a sustained platelet count of at least 50,000/μL or doubling of baseline platelet count after an appropriate course of prior ITP treatment. Intolerance is defined as a documented side effect causing discontinuation of the therapy. 4. The participant has a mean platelet count of \<30,

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT06722235) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Immune Thrombocytopenia Treatment Options in Denver, CO

If you're searching for immune thrombocytopenia treatment options in Denver, CO, this clinical trial (NCT06722235) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all immune thrombocytopenia clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Denver, CO

See all multiple myeloma clinical trials recruiting in Denver — not just this study.

Browse Multiple Myeloma Trials in Denver →

Browse More Trials by Condition

Multiple Myeloma TrialsPulmonary Embolism TrialsThrombocytopenia TrialsIdiopathic Thrombocytopenic Purpura TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO